Stoke Therapeutics, Inc. announced enrollment of the first patient in an observational study of children and adolescents ages 2 to 18 with Dravet syndrome. BUTTERFLY is a two-year observational study that is designed to evaluate seizure frequency and non-seizure comorbidities associated with the disease, including motor and speech impairment, intellectual and developmental disabilities, behavioral deficits and abnormal sleep patterns. Data from the study will support clinical development plans for the company’s lead therapeutic candidate, STK-001, an investigational new treatment for Dravet syndrome.
June 18, 2021
Impaired Social Attention Detected Through Eye Movements in Children With Early-Onset Epilepsy
Children with early-onset epilepsy exhibit task-specific atypical social attention early in the course of the disease. This may be an early marker of impaired social development, and it suggests abnormal social brain development.
June 17, 2021
Febrile Seizure: What Information Can Caregivers Access Through YouTube?
Both the quality and reliability of YouTube videos on febrile seizures were relatively low. Healthcare professionals should be aware that there is misinformation and low-quality information on social media and warn parents of this issue.